Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.53 |
| ▸ | CYP24A1 | Q07973 | 6/20 | 0.53 |
| ▸ | CYP27A1 | Q02318 | 3/20 | 0.53 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.52 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15012600 | 0.92 | GID4 (0.61) | DDB1CRBNCYP19A1CYP24A1CYP27A1 | |
| SCHEMBL15874767 | 0.90 | CYP24A1 (0.60) | CYP19A1CYP24A1CYP27A1CYP26A1DRD2 | |
| SCHEMBL4366122 | 0.90 | CYP24A1 (0.60) | CYP19A1CYP24A1CYP27A1CYP26A1DRD2 | |
| SCHEMBL9144496 | 0.89 | CYP19A1 (0.60) | DDB1CRBNCYP19A1GID4MEN1 | |
| SCHEMBL15874602 | 0.89 | CYP19A1 (0.60) | DDB1CRBNCYP19A1GID4MEN1 | |
| SCHEMBL6669546 | 0.87 | CYP24A1 (0.53) | DDB1CRBNCYP19A1CYP24A1CYP27A1 | |
| SCHEMBL6286139 | 0.86 | CYP19A1 (0.55) | DDB1CRBNCYP19A1GID4MEN1 | |
| SCHEMBL8870256 | 0.84 | CYP19A1 (0.60) | CYP19A1CYP24A1CYP27A1CYP26A1DRD2 | |
| SCHEMBL15263592 | 0.83 | GID4 (0.50) | DDB1CRBNCYP19A1CYP24A1CYP27A1 | |
| SCHEMBL10593732 | 0.83 | CYP24A1 (0.52) | DDB1CRBNCYP19A1CYP24A1CYP27A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200507-A1 | Crystalline Non-Solvated Methanesulfonic Acid Salt of 1-(4-(2-Piperidinylethoxy)Phenoxy)-2-(3-Hydroxyphenyl)-6-Hydroxynaphthalene | ELI LILLY AND COMPANY | 2008-08-21 | — | — | US | disclosed |
| EP-1912962-A2 | CRYSTALLINE NON-SOLVATED METHANESULFONIC ACID SALT OF 1-(4-(2-PIPERIDINYLETHOXY)PHENOXY)-2-(3-HYDROXYPHENYL)-6-HYDROXYNAPHTHALENE | ELI LILLY AND COMPANY (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007016139-A2 | CRYSTALLINE NON-SOLVATED METHANESULFONIC ACID SALT OF 1-(4-(2-PIPERIDINYLETHOXY)PHENOXY)-2-(3-HYDROXYPHENYL)-6-HYDROXYNAPHTHALENE | ELI LILLY AND COMPANY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-7105541-B2 | Naphthyl compounds, intermediates, compositions, and methods of use | ELI LILLY AND COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050054632-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | BRYANT HENRY UHLMAN (US) | 2005-03-10 | — | — | US | disclosed |
| US-6812244-B2 | POSTMENOPAUSAL OSTEOPOROSIS | ELI LILLY AND COMPANY | 2004-11-02 | — | — | US | disclosed |
| US-20040072820-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | BRYANT HENRY UHLMAN (US) | 2004-04-15 | — | — | US | disclosed |
| EP-0835867-B1 | 1-Aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods | LILLY CO ELI (US) | 2003-12-03 | — | — | EP | disclosed |
| US-6593345-B1 | Inhibiting bone loss or bone resorption comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or solvate, and anticholesterol agents | ELI LILLY AND COMPANY | 2003-07-15 | — | — | US | disclosed |
| EP-0826679-B1 | Naphthyl compounds and compositions | LILLY CO ELI (US) | 2001-11-21 | — | — | EP | disclosed |
| US-5929090-A | NOVEL COMPOUNDS FOR TREATING ESTROGEN DEPRIVATION CAUSED BY MENOPAUSE OR OVARIECTOMY; TREATING OSTEOPOROSIS, CARDIOVASCULAR DISEASES, AND ENDOMETRIOSIS | ELI LILLY AND COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5916916-A | USEFUL AS SELECTIVE ESTROGEN RECEPTOR MODULATORS. | ELI LILLY AND COMPANY (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0835868-A1 | 2-Aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
| WO-1998008797-A1 | NAPHTHYL COMPOUNDS, INTERMEDIATES, COMPOSITIONS, AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0826679-A2 | Naphthyl compounds, intermediates, compositions, and method of use | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| US-5021414-A | Antiestrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-06-04 | — | — | US | disclosed |
| US-4904661-A | ANTIESTROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-02-27 | — | — | US | disclosed |
| US-4732912-A | ANTIESTROGENS, ANTITUMOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-22 | — | — | US | disclosed |
| EP-0124369-B1 | PHENOL DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-06-24 | — | — | EP | disclosed |
| EP-0124369-A1 | Phenol derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072820-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | SQLE, NQO1, CYP3A43 | DDB1 3992/4885CRBN 2132/4885CYP19A1 191/4885 |
| US-20080200507-A1 | Crystalline Non-Solvated Methanesulfonic Acid Salt of 1-(4-(2-Piperidinylethoxy)Phenoxy)-2-(3-Hydroxyphenyl)-6-Hydroxynaphthalene | MPHOSPH6, HCN2, HCN1 | DDB1 3398/4885CRBN 2367/4885CYP19A1 4622/4885 |
| US-20050054632-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | SQLE, NQO1, CYP3A43 | DDB1 3992/4885CRBN 2132/4885CYP19A1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.